Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bal PharmaBOM:524824 +4.22%65 ROE % is 17.48% as of Mar. 2026, which is 156% above its 10-year median of 6.82. GuruFocus rates BOM:524824 with a GF Score™ of 65/100 and a GF Value™ of ₹97.37 (Fairly Valued). The stock has 7 warning signs investors should review. Among 937 Drug Manufacturers companies, Bal Pharma ranks better than 56.35% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Bal Pharma's annualized net income for the quarter that ended in Mar. 2026 was ₹144 Mil. Bal Pharma's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹822 Mil. Therefore, Bal Pharma's annualized ROE % for the quarter that ended in Mar. 2026 was 17.48%.
The historical rank and industry rank for Bal Pharma's ROE % or its related term are showing as below:
BOM:524824'
s ROE % Range Over the Past 10 Years
Min: -20.52 Med: 6.82 Max: 10.89
Current: 7.92
During the past 13 years, Bal Pharma's highest ROE % was 10.89%. The lowest was -20.52%. And the median was 6.82%.
BOM:524824's ROE % is ranked better than 56.35% of 937
companies
in the Drug Manufacturers industry
Industry Median: 6.06
vs BOM:524824: 7.92
Bal Pharma (BOM:524824) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Bal Pharma ROE % Related Terms
Bal Pharma ROE % Historical Data
* Premium members only.
The historical data trend for Bal Pharma's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bal Pharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bal Pharma ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bal Pharma's ROE % distribution charts can be found below:
* The bar in red indicates where Bal Pharma's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Bal Pharma (BOM:524824) has a ROE % of 17.48% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bal Pharma and its competitors. This is 156% above median its historical median of 6.82. According to the industry distribution chart, Bal Pharma ranks #409 out of 937 companies in the Drug Manufacturers industry, placing it in the top 43.6%.
Is Bal Pharma's ROE % too high?
Bal Pharma's current ROE % of 17.48% is 156% above median its 10-year median of 6.82. The Drug Manufacturers industry median ROE % is 6.06. Bal Pharma's value of 17.48% is 188.4% above this industry median. Based on the distribution chart, Bal Pharma ranks #409 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bal Pharma has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bal Pharma's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bal Pharma ranks #409 out of 937 companies for ROE %. This puts Bal Pharma in the upper half of its industry. The industry median ROE % is 6.06. Bal Pharma's value of 17.48% is 188.4% above this benchmark. While the company's 10-year median is 6.82 vs. the industry median of 6.06, Bal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.06, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bal Pharma's current ROE % of 17.48% is 188.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bal Pharma and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bal Pharma's current ROE % is 17.48%, which is 156% above median its own 10-year median of 6.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bal Pharma (BOM:524824) is currently considered Fairly Valued. The stock's GF Value™ is ₹97.37, compared to a current price of ₹90.72 — trading 6.8% below its estimated fair value. The current ROE % is 17.48%, which is 156% above median its 10-year median of 6.82 and 188.4% above the Drug Manufacturers industry median of 6.06. Bal Pharma's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Bal Pharma (BOM:524824), the current ROE % is 17.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bal Pharma (BOM:524824) Overvalued in 2026?
Based on GuruFocus' analysis, Bal Pharma stock appears to be undervalued.
The current stock price of ₹90.72 is trading 6.8% below its estimated GF Value™ of ₹97.37.
GuruFocus considers Bal Pharma to be Fairly Valued.
Key valuation signals for BOM:524824:
ROE %: 17.48% (156% above median its 10-year median of 6.82)
GF Value™: ₹97.37 vs. price of ₹90.72 (6.8% below fair value)
Industry Position: 188.4% above the Drug Manufacturers median (#409 of 937)
No single metric tells the full story. See the BOM:524824 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bal Pharma Ltd is a pharmaceutical company. It is principally engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The company specializes in prescription drugs, generic and over-the-counter products, intravenous infusion, and bulk actives.
65GF Score
Get the complete analysis for BOM:524824
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524824 has been successfully added to your 
